Metropolitan Capital Advisors’s AstraZeneca AZN Stock Holding History

Metropolitan Capital Advisors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-36,870	Closed	-$2.64M	–	46
2014 Q3	$2.63M	Buy	+36,870	New	+$2.7M	2.38%	16

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

MAA

Managed Account Advisors Jersey City, New Jersey $121B AUM 7.32% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

EIP

Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

SCCM

Schafer Cullen Capital Management New York $491M AUM 41.48% 1-Year Est. Return

BIM

BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Metropolitan Capital Advisors's AZN Position: Q4 2014 in Review

Metropolitan Capital Advisors sold out of AstraZeneca (AZN) in Q4 2014, closing a stake of 36,870 shares — an estimated $2.64M sold.

Metropolitan Capital Advisors first reported a position in AZN in Q3 2014 and held it in 1 quarter. The position peaked at $2.63M in Q3 2014. 403 funds tracked by Wall St. Rank hold AZN as of Q4 2014.

Metropolitan Capital Advisors reported no remaining AstraZeneca position as of Q4 2014 after selling out during the quarter.
Metropolitan Capital Advisors sold 36,870 AstraZeneca shares in Q4 2014, an estimated $2.64M.
Metropolitan Capital Advisors first reported a position in AstraZeneca in Q3 2014 and held it in 1 quarter.
Metropolitan Capital Advisors's AstraZeneca position peaked at $2.63M in Q3 2014.
403 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2014.

Based on Metropolitan Capital Advisors's 13F filing for Q4 2014, filed 17 Feb 2015.